Bicyclic Diazepanone Troponin Modulators for Skeletal Contractility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neuromuscular diseases are limited, and there is a need for compounds that modulate skeletal muscle contractility through novel mechanisms to improve symptom relief, safety, and therapeutic outcomes.
Innovation Solution
Development of bicyclic 1,4-diazepanone compounds that target the troponin complex of the skeletal sarcomere, modulating the contractility of skeletal muscle fibers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for neuromuscular diseases are used, then existing therapeutic options are available, but treatment effectiveness and safety are limited
Solution Approach 1:
The patent applies parameter changes by developing compounds with modified molecular structures (bicyclic 1,4-diazepanone core with varying substituents) to achieve different binding affinities and functional effects on the troponin complex, thereby improving treatment effectiveness while expanding therapeutic options for neuromuscular diseases
2Adaptability or versatility
If novel compounds targeting troponin complex are developed, then new therapeutic mechanisms are achieved, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the molecule into a core bicyclic 1,4-diazepanone structure and separate substituent groups (R1-R6) that can be independently optimized, allowing systematic exploration of structure-activity relationships to achieve novel therapeutic mechanisms while managing structural complexity
Solution Approach 2:
The patent applies universality by designing a core bicyclic 1,4-diazepanone structure that can serve multiple therapeutic functions by varying substituents, enabling a single compound scaffold to address different neuromuscular conditions through targeted modifications at different positions
Data Source
AI summary
Provided herein are compounds of formula (I):or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X1, X2, Ry, Rz, R1, R2, R3, and R4 are as defined herein.Also provided herein is a pharmaceutically acceptable composition comprising a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.Also provided herein are methods of using a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, to treat various diseases, disorders, and conditions responsive to the modulation of the contractility of the skeletal sarcomere.